Top Biotech Penny Stocks to Watch

Biotech penny stocks are where the most violent moves in the market live, and August 2026 is proving it daily. One FDA headline can double a stock before lunch or cut it in half after dinner. These companies mostly have no revenue, endless dilution, and binary catalysts, which is exactly why traders watch them. We’re not here to bet on cures. We’re here to trade the reaction when the crowd does.

One note before the list. Every name here trades on a major exchange, and none of them belong in a buy-and-hold portfolio. These are trades, and biotech does not owe anybody a bounce.

Want to see what I do each Friday? Check out my Weekend Windfalls strategy!

My 5 biotech penny stocks to watch this August are:

5 Biotech Penny Stocks to Watch

Get my weekly watchlist, free

Sign up to jump start your trading education!

Send me your weekly watchlist

100% Privacy. I will never spam you!

My top 5 biotech penny stocks for August 2026 are:

• SELLAS Life Sciences Group (NASDAQ: SLS) — The Phase 3 Countdown Trade
• Capricor Therapeutics (NASDAQ: CAPR) — The 83% One-Day FDA Squeeze
• Recursion Pharmaceuticals (NASDAQ: RXRX) — The AI Biotech Near Its Lows
• Nuwellis (NASDAQ: NUWE) — The Micro-Float That Tripled Overnight
• China Pharma Holdings (AMEX: CPHI) — The $1-to-$19 Supernova

Before you send any orders, know this: I have NO plans to trade these unless they fit my preferred setups. This is a watchlist, not a buy list. Do your own research before anything goes near your portfolio. The best traders watch far more than they trade.

Sign up for my NO-COST weekly watchlist to get my latest picks!

What is the most promising biotech penny stock?

A name with a defined catalyst like SELLAS Life Sciences (NASDAQ: SLS) is a reasonable pick, since its Phase 3 AML readout is the kind of binary event that creates huge volume. But remember, we’re traders, not investors. We watch these for the move around the event, not for predictions about which drug gets approved.

What are the top 3 biotech penny stocks to watch now?

As long as the price action supports it, my top 3 from this list are:

• SELLAS Life Sciences Group (NASDAQ: SLS)
• Capricor Therapeutics (NASDAQ: CAPR)
• Nuwellis (NASDAQ: NUWE)

Are any biotech penny stocks safe?

No. Biotech penny stocks are the most binary trading vehicles in the market. Most of these companies burn cash, dilute shareholders, and live or die on FDA decisions. That risk is exactly what creates the volatility we trade. Size small, cut losses fast, and never marry a drug story.

Let’s get to the picks.

SELLAS Life Sciences Group (NASDAQ: SLS) — The Phase 3 Countdown Trade

My first biotech penny stock pick is SELLAS Life Sciences Group (NASDAQ: SLS).

This is the cleanest catalyst setup on my list. SLS ran from $1.39 to nearly $16 inside a year, up more than 500%* over twelve months, and trades near $12.78 as the market counts down to Phase 3 REGAL trial results for its lead leukemia drug. The trial hit its required event count, so the readout clock is running.

The tape shows the crowd positioning. The stock rose in 8 of 10 recent sessions, and one analyst shop just jacked its target from $25 to $35. But understand what this is: a pre-revenue biotech that also took an adverse arbitration ruling in late July. If the data disappoints, the same crowd that bought it at $13 will sell it at $5 without blinking.

• Bullish scenario: Continued momentum into the readout could retest the highs near $16, and strong data gaps it well beyond.
• Bearish scenario: A failed trial or another delay could round-trip this toward the mid-single digits fast.

Read more: SELLAS Stock Rides Momentum Into Its Phase 3 Readout

Capricor Therapeutics (NASDAQ: CAPR) — The 83% One-Day FDA Squeeze

My second biotech penny stock pick is Capricor Therapeutics (NASDAQ: CAPR).

Study this one, because it’s a full biotech cycle in two months. An FDA advisory committee voted 9-3 against its Duchenne muscular dystrophy drug and the stock lost roughly a third of its value in a day. Securities lawsuits piled on. Then the FDA said it was willing to review an amended application, and CAPR ripped 83%* in a single session, with Cantor Fitzgerald upgrading and yanking its target from $3.50 to $28.

The 52-week range says everything: $2.96 to $40.37. It trades near $7 now with a Q2 loss of 70 cents a share, no revenue, and class actions still pending. Nobody knows what this is worth, which is why it moves like this.

• Bullish scenario: Continued regulatory progress could keep the squeeze alive toward the low teens, where prior support sat.
• Bearish scenario: Any negative FDA language sends it back toward the $3s, and the lawsuits keep a lid on every rally.

Read more: Capricor Stock Rips On Its FDA Review Update

Recursion Pharmaceuticals (NASDAQ: RXRX) — The AI Biotech Near Its Lows

My third biotech penny stock pick is Recursion Pharmaceuticals (NASDAQ: RXRX).

RXRX is the crossover play, an AI drug-discovery company trading like a beaten-down biotech near $3.35, close to its 52-week low of $2.77 after touching $7.18. The AI story pulls in retail every time the sector runs, and partnerships with Roche, Genentech, and Sanofi give it real headlines to trade.

Q2 showed a $131 million net loss, but management cut operating expenses and advanced its first Roche-Genentech neuroscience target. Here’s the trader’s detail: short interest has run around 30% of the float. A crowded short on a beaten-down AI-biotech name is squeeze fuel if any catalyst lands.

• Bullish scenario: An AI-sector rotation or pipeline headline could squeeze this back toward $5, where analysts cluster.
• Bearish scenario: A break of the 52-week low near $2.77 opens a slide with nothing underneath it.

Read more: Recursion Stock In Focus As AI Drug Discovery Advances

Nuwellis (NASDAQ: NUWE) — The Micro-Float That Tripled Overnight

My fourth biotech penny stock pick is Nuwellis (NASDAQ: NUWE).

NUWE is a tiny medical-device company with a market cap around $30 million, and that micro size is the whole trade. It spiked more than 100%* in a single premarket session recently, the kind of move only a stock this small can make. I traded it myself for a quick gain during its late-July run, and it moves so fast premarket that if you’re not early, you’re late.

There is no fundamental story here worth believing. This is float math: tiny supply, sudden demand, violent moves in both directions. These runs fail as fast as they start, so sell into strength and never overstay.

• Bullish scenario: Another volume surge could produce a repeat spike, since traders remember former runners and set alerts.
• Bearish scenario: No volume means no trade, and these fade back toward their base until the next catalyst.

Read more: Nuwellis Stock Spikes As Volume Floods The Micro-Float

China Pharma Holdings (AMEX: CPHI) — The $1-to-$19 Supernova

My fifth biotech penny stock pick is China Pharma Holdings (AMEX: CPHI).

CPHI put on one of the wildest Supernova runs of the summer, going from the $1s to the $19s, crashing to the $6s, and bouncing back toward the $16s inside two days. The exchange flagged unusual market activity across three separate July sessions, and the company itself said it had no news to explain the move. That tells you everything: this trades on crowd emotion, not fundamentals.

The history is a warning label. CPHI did a 1-for-10 reverse split last year, the classic move of a penny stock fighting to stay listed. Former Supernovas like this make repeated comeback attempts on volume, and by and large those comebacks fail. Trade the spikes, expect the fades.

• Bullish scenario: A fresh volume surge could trigger another comeback attempt, and these can run multiple dollars in minutes.
• Bearish scenario: Without volume, failed Supernovas bleed back toward their pre-spike range, and the reverse-split history says dilution is always on the table.

Read more: China Pharma Stock Whipsaws As Exchange Flags Unusual Activity

*Past performance does not indicate future results

What Are Biotech Penny Stocks?

Biotech penny stocks refer to shares of small biotech companies that trade for less than $5 — stocks in pharmaceutical companies with drugs in development. Recent biotech spikers have come from the following areas:

• Companies working on COVID-19 vaccines and tests
• Companies working in pandemic relief and control
• Firms researching cancer medicines and immuno-oncology drugs
• Companies developing medicines for rare disorders

These companies are usually desperate for cash from investors. They need it to send their products through multiple phases of testing and stages of trials.

That’s their focus in the markets — to keep stock prices high by selling their progress. When their share prices grow enough, they’ll dilute to cash in, leaving bag holders with big losses…

They’re known to be extremely volatile. One minute they’re flying high on positive headlines — the next they’re down due to bad trial results, side effects on patients, FDA approval issues, or stock dilution.

That’s why I ride the hype but never believe it.

Penny stocks are some of the sketchiest stocks in the market. They suck in newbies with their upside, and these newbies start to believe as share value increases…

There are ways to profit off biotech stocks — as long as you know how the niche works. I learned by making my own mistakes.

I started trading in high school. By the time I graduated college, I had grown my small account from $12,415 to roughly $2 million. I also made some world-class blunders. Read all about it in my best-selling no-cost book, “An American Hedge Fund.”

I’ve now made over $7.9 million in profits. So far, I’ve taught 50+ millionaire students how to trade with a small account in my Trading Challenge.

**Apply for the Trading Challenge Today**

Challenge students get access to all my top tips and trading education resources — including my daily watchlists.

To become a self-sufficient trader, you have to learn how to build your own watchlist. So study up and learn the logic behind my stock picks…

Is It a Wise Decision to Invest in Biotech Penny Stocks?

These stocks are high-risk, high-reward plays in the biotech industry, offering potential for significant gains but also carrying substantial risk. In this article, we’ll delve into the pros and cons of investing in biotech penny stocks, the factors to consider, and why some biotech penny stocks might be better picks than others.

While the focus here is on biotech stocks, you might be wondering if penny stocks can be a long-term investment. The answer is nuanced. While they’re generally considered short-term plays, there are exceptions. Want to know more about how to approach penny stocks for the long haul? Here’s a guide that delves into long-term strategies with penny stocks.

Biotech Stocks Under $5

The allure of hot sector stocks, especially when they’re also penny stocks, is undeniable. These stocks present a unique blend of opportunity and volatility. The biotech industry is booming, with advancements and applications spreading across various sectors, from drug development to gene editing, making biotech stocks a magnet for investors looking for the next big breakthrough. The gains here can be proportionately greater than those from more established stocks, mainly because even minor positive developments or clinical trial results can send their prices soaring.

However, it’s crucial to approach these opportunities with a clear strategy and an understanding of the risks involved. The volatility of penny stocks, combined with the speculative nature of biotech ventures, means that while the potential for rapid gains is significant, the risk of losses is equally high. Conduct thorough research, looking beyond the hype. And never invest in these stocks — only trade them.

Remember, the key to success in trading biotech stocks under $5 is not just about jumping on every opportunity but being selective and strategic. It’s about leveraging the explosive potential of the biotech sector while managing risk meticulously. By focusing on companies with the potential to lead in their niche, traders can capitalize on the disproportionate gains that these penny stocks offer, all while keeping their investment strategy tight and cutting losses quickly.

My best tip is to look beyond biotech penny stocks — healthcare and medical stocks give traders the same upside potential and trade-worthy volatility. Researching these stocks can help you diversify your trading portfolio and give you a better chance to be watching a hot stock when it pops off. Check out my watchlist of Healthcare and Medical Stocks.

What Is the Best Biotech Stock To Buy Right Now?

I can’t tell you the “best” biotech stock to buy right now because the market is always changing. What I can tell you is to look at factors like market cap, liquidity, and EPS (earnings per share). These are crucial indicators that can give you an edge. I’ve been trading for years, and I can tell you that understanding these metrics is a game-changer.

You can get your intel from TipRanks links and Wall Street analysts — but remember, they’re not always right. You’ve got to do your own research. Dive into the company’s pipeline, check out their science, and maybe even look into the careers of the top executives. The more you know, the better your strategy will be.

There’s no need to limit yourself to sketchy biotechs in the US — check out this list of top pharmaceutical stocks in Canada! Vancouver is a hub of biotech activity, and Toronto is where insulin was discovered so you know it isn’t Canada’s first biotech rodeo. For more ideas, visit my article on the Top Pharmaceutical Stocks in Canada.

Why Other Biotech Penny Stocks Were Not Chosen

When it comes to biotech penny stocks, not all are created equal. Some have strong growth potential backed by innovative therapies and treatments for diseases, while others might just be riding the hype. It’s crucial to conduct thorough analysis before diving in. Let’s explore why some biotech penny stocks might not make the cut.

• Clinical Indications and Approvals: Biotech companies often focus on specific clinical indications. If a company doesn’t have any therapies or treatments that have received approvals or shown promise in clinical trials, it’s a red flag. Regulatory approvals are milestones that can significantly impact a biotech company’s stock price.
• Financial Health: Revenue and Debt: Another critical factor is the company’s financial health. A biotech company with high debt and low revenue is a risky investment. Always check the balance sheet. Brokers and analysts often provide this information, but it’s best to do your own due diligence. Look at rates of revenue growth and how the company manages its debt.

Get the List of Penny Stocks I’m Watching Delivered to Your Inbox

Want to know the top stocks I’m watching each week? I’ve got a watchlist for that. I’ll send my top penny stocks to watch right to your inbox every week. It can help you learn the process I follow for every stock.

Remember: the stocks in my newsletters aren’t automatic buys. You should only listen to your own opinions. Do your own due diligence and research before considering a stock for your trading portfolio.

👉🏼 SUBSCRIBE to my no-cost weekly stock watchlist here.

How do I find the hottest stocks to trade? I use Breaking News Chat every day — it helped me make over $1 million in trading profits in 2021, when biotech news was behind many of the best spikers I’ve seen in my 25+ years trading. I seriously think every trader should have this tool working for them. It’s one of the best trading platforms out there.

Try Breaking News Chat for only $17!

Things You Need to Know Before Investing in Biotech Penny Stocks

Thanks to their volatility, biotechs can drain your investments faster than you can enter the ticker name in the order window. Banks and traditional finance institutions often steer clear of these for a reason. But if you’re like me, you see the potential for massive gains. I’ve been teaching trading strategies for years, and one thing I always emphasize is risk management.

Before you even think about diving in, understand the economy you’re playing in. Look at dividends, if any, and how the company is positioned in its region. Check out exchanges where the stock is listed; some are more reputable than others. And for heaven’s sake, don’t put all your eggs in one basket. Diversification is key.

If you’re already committed to doing your homework, why not take it a step further? There are biotech companies out there that are just waiting to be discovered. These hot biotechs could be the next big thing, and your research could lead you right to them.

Interested in finding these hidden gems? Check out this list of former runners. And remember…

Former runners can run again!

How To Trade Biotech Penny Stocks The Right Way

So you’re still with me? Good. Hopefully, the Instagram trading influencers have already clicked off to go blow up their accounts. Trading biotech penny stocks the right way involves a well-thought-out strategy. I’ve been in this game long enough to know that you can’t rely on luck. You need a solid plan, and you need to stick to it.

First off, don’t ignore the news and events surrounding the biotech sector. This industry is heavily influenced by views from the scientific community, FDA approvals, and other significant events. Keep an eye on these, and you’ll be ahead of the game. Also, consider using credit cards wisely to manage your liquidity, but be cautious of the risks involved.

How do you get ahead of the game? That’s all about finding a biotech penny stock before it makes headlines. It’s possible, but it requires a specific approach. Learn my method for finding penny stocks pre-spike here.

Legal Considerations When Trading Biotech Penny Stocks

When trading biotech penny stocks and other small-cap stocks, you need to understand the legal considerations specific to these securities. It’s not that you’re going to make a mistake and get your account locked down — that’s something you’ve got to watch out for in all stocks if you’re under the PDT — but keeping your eye off the ball with sketchy therapeutics companies can cost you money.

The biotech sector is heavily regulated, and this complexity adds layers of risk. Regulators are on the lookout for snake-oil salesmen behind the latest penny stock “innovations” — these are the major ways that biotech stocks are affected:

• Complex regulatory environment
• High risk of volatile price movements
• Increased scrutiny from regulatory bodies
• Potential for insider trading violations
• Mandatory disclosure requirements

Compliance With SEC Regulations

The Securities and Exchange Commission (SEC) plays a big role in regulating stocks. This is what your favorite biotech penny stock should be aware of:

1. Registration of Securities: Companies must register their securities with the SEC.
2. Disclosure of Information: Detailed financial information must be disclosed.
3. Reporting Requirements: Regular financial reports must be filed.
4. Prohibition of Fraudulent Activities: Strict rules against fraud and market manipulation.
5. Broker-Dealer Requirements: Brokers must comply with specific regulations when handling penny stocks.

Awareness of Penny Stock Rules (SEC Rule 15g-9)

Penny stocks are defined as stocks trading for less than $5 per share and are subject to SEC Rule 15g-9. This rule aims to protect investors from high-risk investments by ensuring that brokers follow specific compliance procedures.

• Brokers must provide a disclosure document outlining the risks of penny stocks.
• Investors must sign and return a copy of this document before any trades are executed.
• Brokers must determine that penny stock transactions are suitable for the investor.
• Monthly account statements must be provided to the investor.

Understanding Insider Trading Laws

Insider trading involves trading a public company’s stock based on non-public, material information about the company. This practice is illegal and carries severe consequences, especially in the biotech sector, where insider information can significantly impact stock prices.

This is one of the big “tells” behind sketchy biotech stocks that you absolutely should not be holding overnight. Watch out for the following:

• Fines and penalties imposed by the SEC
• Criminal charges leading to imprisonment
• Permanent bans from trading activities
• Significant reputational damage

Disclosure Requirements

Several types of disclosures are legally required when trading biotech penny stocks to maintain transparency and protect investors.

1. Material Event Disclosure: Significant events like mergers or product approvals.
2. Financial Statement Disclosure: Detailed and accurate financial statements.
3. Management Discussion and Analysis: Insight into financial health and management strategies.
4. Risk Factor Disclosure: Potential risks involved in the investment.
5. Insider Holdings Disclosure: Information about shares held by insiders.

These disclosures help maintain market integrity and protect investors by ensuring they have access to all material information before making investment decisions.

Risks of Market Manipulation

Market manipulation is a significant risk in the penny stock market, especially in the biotech sector. As always, do your due diligence, be skeptical of overly positive news, and monitor trading volumes for unusual spikes.

And watch out for these tricks!

• Promoter pumps: Artificially inflating stock prices before selling off.
• Spoofing: Placing and then canceling large orders to manipulate prices.
• Wash trading: Simultaneously buying and selling shares to create fake volume.

Impact of Regulatory Approvals and Rejections

The prices of biotech penny stocks are highly sensitive to FDA regulatory approvals and rejections. A positive FDA decision can send stock prices soaring, while a rejection can lead to significant losses.

Biotech Penny Stocks: The Bottom Line

Penny stock trading is a great way to build your account as a new trader. Biotech penny stocks are some of the hottest movers on the market — but this volatility can cut both ways..

Key Considerations:

• A lot of penny stocks are shady. Risk in biotech penny stocks can be heightened due to limited company information and unsavory promotion. When the price gets up high enough, nine times out of 10 these companies will do new share offerings, tanking share price.
• There’s a possibility for big gains. I trade biotech penny stocks because you can trade conservatively and still rack up gains. These stocks can go supernova at any time. Aim for “the meat of the move.”
• These companies are often young. Some biotech penny stocks are newer companies, and can dramatically shift their market trajectory and valuation.

Trading isn’t rocket science. It’s a skill you build and work on like any other. Trading has changed my life, and I think this way of life should be open to more people…

I’ve built my Trading Challenge to pass on the things I had to learn for myself. It’s the kind of community that I wish I had when I was starting out.

We don’t accept everyone. If you’re up for the challenge — I want to hear from you.

Apply to the Trading Challenge here.

Trading is a battlefield. The more knowledge you have, the better prepared you’ll be.

Have you traded penny biotech stocks? Write “I always trade with a plan” in the comments!

Biotech Penny Stock FAQs

What Biotech Sectors Should I Focus On?

When it comes to biotechnology, you’ve got a smorgasbord of options. Genomics and cell therapies are hot right now. Don’t overlook stem cells; they’re a cornerstone in healthcare solutions. Diversifying across these sectors can be a smart move.

What Investment Vehicles Are Suitable for Biotech Penny Stocks?

You’ll hear me say it a million times: diversification is key. Consider ETFs that focus on biotech. If you’re into individual stocks, keep an eye on ipo listings and blue-chip companies that have a biotech arm. Setting a price target can help, and don’t forget, you can also use an ira to hold these assets.

How Do Market Dynamics Affect Biotech Penny Stocks?

Market dynamics are the bread and butter of trading. Keep an eye on buyers and their positions, especially in penny shares and penny stocks. Pharmaceutical stock can be volatile, so understanding the market sentiment is crucial.

How Can I Analyze Biotech Penny Stocks?

We’re here for the long haul, so get familiar with the tools of the trade. A stock biotech chart is invaluable for technical analysis. Keep a stocks list for quick reference, and don’t forget to compare pharma stocks to get a broader view.